Log In
BCIQ
Print this Print this
 

SynGEM

  Manage Alerts
Collapse Summary General Information
Company Mucosis B.V.
DescriptionRespiratory syncytial virus (RSV) vaccine that uses bacterium-like-particle (BLP)-based Mimopath technology carrying trimeric fusion proteins
Molecular Target Not applicable
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine: Viral vaccine
Latest Stage of DevelopmentPhase I
Standard IndicationRespiratory syncytial virus (RSV)
Indication DetailsPrevent respiratory syncytial virus (RSV) infections; Vaccinate against respiratory syncytial virus (RSV) infection
Regulatory Designation
PartnerChangchun BCHT Biotechnology Co.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

04/21/2014

Undisclosed

0

Undisclosed

Get a free BioCentury trial today